BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $903.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by equities research analysts at BMO Capital Markets from $950.00 to $903.00 in a report issued on Tuesday. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target suggests a potential upside of 25.99% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Up 2.8 %

Shares of NASDAQ:REGN opened at $716.72 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market capitalization of $78.76 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The firm has a fifty day moving average of $718.04 and a 200 day moving average of $916.32. Regeneron Pharmaceuticals has a 52-week low of $642.00 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $11.86 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bailard Inc. lifted its position in Regeneron Pharmaceuticals by 10.1% during the fourth quarter. Bailard Inc. now owns 13,422 shares of the biopharmaceutical company’s stock valued at $9,561,000 after purchasing an additional 1,236 shares during the period. Smartleaf Asset Management LLC raised its position in Regeneron Pharmaceuticals by 8.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 952 shares of the biopharmaceutical company’s stock worth $669,000 after acquiring an additional 72 shares during the period. Keynote Financial Services LLC raised its position in Regeneron Pharmaceuticals by 8.2% in the fourth quarter. Keynote Financial Services LLC now owns 539 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 41 shares during the period. John G Ullman & Associates Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $2,361,000. Finally, Nixon Peabody Trust Co. raised its position in Regeneron Pharmaceuticals by 8.0% in the fourth quarter. Nixon Peabody Trust Co. now owns 430 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 32 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.